Johnson & Johnson (NYSE:JNJ) Shares Sold by Staley Capital Advisers Inc.

Staley Capital Advisers Inc. lowered its holdings in Johnson & Johnson (NYSE:JNJ) by 1.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 296,567 shares of the company’s stock after selling 5,095 shares during the period. Johnson & Johnson comprises 1.9% of Staley Capital Advisers Inc.’s holdings, making the stock its 18th biggest holding. Staley Capital Advisers Inc.’s holdings in Johnson & Johnson were worth $42,889,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. IFS Advisors LLC increased its stake in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares in the last quarter. Bay Harbor Wealth Management LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter worth about $32,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Johnson & Johnson in the third quarter worth approximately $35,000. Activest Wealth Management acquired a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $40,000. Finally, NewSquare Capital LLC lifted its position in shares of Johnson & Johnson by 145.8% in the 4th quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock valued at $42,000 after acquiring an additional 172 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Trading Up 0.5 %

Johnson & Johnson stock opened at $167.57 on Tuesday. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company’s fifty day moving average price is $153.44 and its two-hundred day moving average price is $156.28. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The company has a market capitalization of $403.45 billion, a price-to-earnings ratio of 25.20, a PEG ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the firm posted $2.29 EPS. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on JNJ shares. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Bank of America raised their price objective on Johnson & Johnson from $159.00 to $171.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 5th. Wells Fargo & Company dropped their target price on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Finally, Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a report on Monday. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.